May 08, 2025

FDA Warns Physicians of Tianeptine Dangers

The FDA warns physicians about unapproved tianeptine products that are linked to severe adverse events, including dependence, toxicity, and death.

Conexiant

May 07, 2025

Dr. Vinay Prasad Shakes Up FDA Leadership

The FDA has appointed Vinay Prasad as its new vaccine chief, shaking up biotech stocks and signaling potential shifts in drug approvals.

Reuters

May 07, 2025

FDA Approves Low-Dose Chlorthalidone Tablet

The FDA has approved HemiClor, a 12.5-mg chlorthalidone tablet, providing patients with a low-dose option.

Conexiant

May 06, 2025

FDA Approves TAVR Platform for Asymptomatic AS

The FDA has approved the SAPIEN 3 TAVR platform for patients with asymptomatic severe aortic stenosis based on data from the EARLY TAVR trial.

Conexiant

May 05, 2025

FDA Monthly Round-up: Key April Updates

April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.

Conexiant

May 01, 2025

Health Care Shortage: Who’s Left Out?

“The ER then says, ‘OK, you should follow up with your primary care provider,’ and they’re like, ‘We don’t have one.’”

KFF Health News

April 29, 2025

Foley Catheter Management: New Best Practices, Pitfalls

Foley catheter use is associated with a wide range of complications, from infections to urethral erosion.

Conexiant

April 28, 2025

Oral Semaglutide Cuts Cardiovascular Event Risk

Oral semaglutide was superior to placebo in reducing the risk of major adverse cardiovascular events, researchers reported in the SOUL trial involving over 9,600 adults with high-risk type 2 diabetes.

Conexiant

April 25, 2025

FDA Approves Penpulimab-kcqx for NPC

The FDA approved penpulimab-kcqx for first line and previously treated recurrent or metastatic non-keratinizing nasopharyngeal carcinoma.

Conexiant